drugset / Trial / NCT02512172
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Phase 1
Completed
27 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Celgene Corporation · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is being done to test the safety and effectiveness of the combination of intravenous (IV) romidepsin and/or oral 5-azacitidine with IV MK-3475 in people with microsatellite stable (MSS) advanced colorectal cancer.
Timeline
- Start
- 2016-02-19
- Primary completion
- 2021-11-20
- Completion
- 2021-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 300 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Romidepsin | Peptide | 7 mg/m2 | Intravenous |
| Subject | Romidepsin | Peptide | 14 mg/m2 | Intravenous |